172 related articles for article (PubMed ID: 31932495)
1. A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial.
Karn T; Meissner T; Weber KE; Solbach C; Denkert C; Engels K; Fasching PA; Sinn BV; Schrader I; Budczies J; Marmé F; Müller V; Holtrich U; Gerber B; Schem C; Young BM; Hanusch C; Stickeler E; Huober J; van Mackelenbergh M; Leyland-Jones B; Fehm T; Nekljudova V; Untch M; Loibl S
Clin Cancer Res; 2020 Apr; 26(8):1896-1904. PubMed ID: 31932495
[TBL] [Abstract][Full Text] [Related]
2. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
3. Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial.
Kimbung S; Markholm I; Bjöhle J; Lekberg T; von Wachenfeldt A; Azavedo E; Saracco A; Hellström M; Veerla S; Paquet E; Bendahl PO; Fernö M; Bergh J; Loman N; Hatschek T; Hedenfalk I;
Int J Cancer; 2018 Feb; 142(3):618-628. PubMed ID: 28940389
[TBL] [Abstract][Full Text] [Related]
4. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy.
Liu S; Duan X; Xu L; Xin L; Cheng Y; Liu Q; Ye J; Zhang S; Zhang H; Zhu S; Li T; Liu Y
Breast Cancer Res Treat; 2015 Nov; 154(2):239-49. PubMed ID: 26498019
[TBL] [Abstract][Full Text] [Related]
5. Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial.
Dieci MV; Prat A; Tagliafico E; Paré L; Ficarra G; Bisagni G; Piacentini F; Generali DG; Conte P; Guarneri V
Ann Oncol; 2016 Oct; 27(10):1867-73. PubMed ID: 27484801
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
7. PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer.
Ohara AM; Naoi Y; Shimazu K; Kagara N; Shimoda M; Tanei T; Miyake T; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2019 Feb; 173(3):533-543. PubMed ID: 30361874
[TBL] [Abstract][Full Text] [Related]
8. Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study.
Hein A; Lambrechts D; von Minckwitz G; Häberle L; Eidtmann H; Tesch H; Untch M; Hilfrich J; Schem C; Rezai M; Gerber B; Dan Costa S; Blohmer JU; Schwedler K; Kittel K; Fehm T; Kunz G; Beckmann MW; Ekici AB; Hanusch C; Huober J; Liedtke C; Mau C; Moisse M; Müller V; Nekljudova V; Peuteman G; Rack B; Rübner M; Van Brussel T; Wang L; Weinshilboum RM; Loibl S; Fasching PA
Int J Cancer; 2015 Dec; 137(12):2981-8. PubMed ID: 26100253
[TBL] [Abstract][Full Text] [Related]
9. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
[TBL] [Abstract][Full Text] [Related]
10. Brief-exposure to preoperative bevacizumab reveals a TGF-β signature predictive of response in HER2-negative breast cancers.
Varadan V; Kamalakaran S; Gilmore H; Banerjee N; Janevski A; Miskimen KL; Williams N; Basavanhalli A; Madabhushi A; Lezon-Geyda K; Bossuyt V; Lannin DR; Abu-Khalaf M; Sikov W; Dimitrova N; Harris LN
Int J Cancer; 2016 Feb; 138(3):747-57. PubMed ID: 26284485
[TBL] [Abstract][Full Text] [Related]
11. Gene Expression Signatures Predictive of Bevacizumab/Erlotinib Therapeutic Benefit in Advanced Nonsquamous Non-Small Cell Lung Cancer Patients (SAKK 19/05 trial).
Franzini A; Baty F; Macovei II; Dürr O; Droege C; Betticher D; Grigoriu BD; Klingbiel D; Zappa F; Brutsche MH
Clin Cancer Res; 2015 Dec; 21(23):5253-63. PubMed ID: 25922429
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy.
De Angelis C; Nagi C; Hoyt CC; Liu L; Roman K; Wang C; Zheng Y; Veeraraghavan J; Sethunath V; Nuciforo P; Wang T; Tsimelzon A; Mao S; Hilsenbeck SG; Trivedi MV; Cataldo ML; Pavlick A; Wolff AC; Weigelt B; Reis-Filho JS; Prat A; Gutierrez C; Osborne CK; Rimawi MF; Schiff R
Clin Cancer Res; 2020 Feb; 26(3):738-745. PubMed ID: 31653641
[TBL] [Abstract][Full Text] [Related]
13. TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer.
Vaklavas C; Roberts BS; Varley KE; Lin NU; Liu MC; Rugo HS; Puhalla S; Nanda R; Storniolo AM; Carey LA; Saleh MN; Li Y; Delossantos JF; Grizzle WE; LoBuglio AF; Myers RM; Forero-Torres A;
Breast Cancer Res; 2020 Feb; 22(1):22. PubMed ID: 32070401
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.
Li XB; Krishnamurti U; Bhattarai S; Klimov S; Reid MD; O'Regan R; Aneja R
Am J Clin Pathol; 2016 Jun; 145(6):871-8. PubMed ID: 27298399
[TBL] [Abstract][Full Text] [Related]
15. Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer.
Brodsky AS; Xiong J; Yang D; Schorl C; Fenton MA; Graves TA; Sikov WM; Resnick MB; Wang Y
BMC Cancer; 2016 Apr; 16():274. PubMed ID: 27090210
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial.
Janning M; Müller V; Vettorazzi E; Cubas-Cordova M; Gensch V; Ben-Batalla I; Zu Eulenburg C; Schem C; Fasching PA; Schnappauf B; Karn T; Fehm T; Just M; Kühn T; Holms F; Overkamp F; Krabisch P; Rack B; Denkert C; Untch M; Tesch H; Rezai M; Kittel K; Pantel K; Bokemeyer C; Loibl S; von Minckwitz G; Loges S
Int J Cancer; 2019 Aug; 145(3):857-868. PubMed ID: 30694523
[TBL] [Abstract][Full Text] [Related]
17. Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial.
Ali HR; Dariush A; Thomas J; Provenzano E; Dunn J; Hiller L; Vallier AL; Abraham J; Piper T; Bartlett JMS; Cameron DA; Hayward L; Brenton JD; Pharoah PDP; Irwin MJ; Walton NA; Earl HM; Caldas C
Ann Oncol; 2017 Aug; 28(8):1832-1835. PubMed ID: 28525534
[TBL] [Abstract][Full Text] [Related]
18. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
Loibl S; von Minckwitz G; Schneeweiss A; Paepke S; Lehmann A; Rezai M; Zahm DM; Sinn P; Khandan F; Eidtmann H; Dohnal K; Heinrichs C; Huober J; Pfitzner B; Fasching PA; Andre F; Lindner JL; Sotiriou C; Dykgers A; Guo S; Gade S; Nekljudova V; Loi S; Untch M; Denkert C
J Clin Oncol; 2014 Oct; 32(29):3212-20. PubMed ID: 25199759
[TBL] [Abstract][Full Text] [Related]
19. Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers.
Haugen MH; Lingjærde OC; Hedenfalk I; Garred Ø; Borgen E; Loman N; Hatschek T; Børresen-Dale AL; Naume B; Mills GB; Mælandsmo GM; Engebraaten O
JCO Precis Oncol; 2021; 5():. PubMed ID: 34036235
[TBL] [Abstract][Full Text] [Related]
20. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.
Denkert C; Loibl S; Noske A; Roller M; Müller BM; Komor M; Budczies J; Darb-Esfahani S; Kronenwett R; Hanusch C; von Törne C; Weichert W; Engels K; Solbach C; Schrader I; Dietel M; von Minckwitz G
J Clin Oncol; 2010 Jan; 28(1):105-13. PubMed ID: 19917869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
